AVITA Medical, Inc. (RCEL)
RCEL Stock Price Chart
Explore AVITA Medical, Inc. interactive price chart. Choose custom timeframes to analyze RCEL price movements and trends.
RCEL Company Profile
Discover essential business fundamentals and corporate details for AVITA Medical, Inc. (RCEL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
14 May 2012
Employees
260.00
Website
https://www.avitamedical.comCEO
James M. Corbett
Description
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
RCEL Financial Timeline
Browse a chronological timeline of AVITA Medical, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.38, while revenue estimate is $29.51M.
Earnings released on 7 Aug 2025
EPS came in at -$0.38 falling short of the estimated -$0.26 by -46.15%, while revenue for the quarter reached $12.03M , missing expectations by -70.09%.
Earnings released on 8 May 2025
EPS came in at -$0.53 falling short of the estimated -$0.39 by -35.90%, while revenue for the quarter reached $11.63M , missing expectations by -68.87%.
Earnings released on 13 Feb 2025
EPS came in at -$0.44 falling short of the estimated -$0.30 by -46.67%, while revenue for the quarter reached $11.39M , missing expectations by -63.94%.
Earnings released on 7 Nov 2024
EPS came in at -$0.62 falling short of the estimated -$0.42 by -47.62%, while revenue for the quarter reached $13.52M , missing expectations by -61.77%.
Earnings released on 8 Aug 2024
EPS came in at -$0.60 falling short of the estimated -$0.59 by -1.69%, while revenue for the quarter reached $10.13M , missing expectations by -31.22%.
Earnings released on 13 May 2024
EPS came in at -$0.73 falling short of the estimated -$0.26 by -180.77%, while revenue for the quarter reached $7.21M , missing expectations by -34.79%.
Earnings released on 22 Feb 2024
EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%, while revenue for the quarter reached $9.66M , missing expectations by -33.35%.
Earnings released on 9 Nov 2023
EPS came in at -$0.34 surpassing the estimated -$0.53 by +35.85%, while revenue for the quarter reached $13.58M , beating expectations by +1.60%.
Earnings released on 10 Aug 2023
EPS came in at -$0.41 falling short of the estimated -$0.34 by -20.59%, while revenue for the quarter reached $11.72M , beating expectations by +3.52%.
Earnings released on 11 May 2023
EPS came in at -$0.37 falling short of the estimated -$0.22 by -68.18%, while revenue for the quarter reached $7.08M , missing expectations by -37.42%.
Earnings released on 23 Feb 2023
EPS came in at -$0.21 surpassing the estimated -$0.32 by +34.38%, while revenue for the quarter reached $6.46M , missing expectations by -37.45%.
Earnings released on 10 Nov 2022
EPS came in at -$0.22 surpassing the estimated -$0.32 by +31.25%, while revenue for the quarter reached $9.21M , beating expectations by +23.10%.
Earnings released on 11 Aug 2022
EPS came in at -$0.25 surpassing the estimated -$0.35 by +28.57%, while revenue for the quarter reached $8.30M , beating expectations by +13.45%.
Earnings released on 12 May 2022
EPS came in at -$0.38 falling short of the estimated -$0.36 by -5.56%, while revenue for the quarter reached $7.56M , beating expectations by +4.39%.
Earnings released on 28 Feb 2022
EPS came in at -$0.34 surpassing the estimated -$0.43 by +20.93%, while revenue for the quarter reached $6.92M , missing expectations by -76.94%.
Earnings released on 8 Nov 2021
EPS came in at -$0.24 surpassing the estimated -$0.40 by +40.00%, while revenue for the quarter reached $5.08M , missing expectations by -27.43%.
Earnings released on 26 Aug 2021
EPS came in at -$0.19 surpassing the estimated -$0.32 by +40.63%, while revenue for the quarter reached $7.74M , missing expectations by -6.51%.
Earnings released on 13 May 2021
EPS came in at -$0.26 surpassing the estimated -$0.38 by +31.58%, while revenue for the quarter reached $8.78M , missing expectations by -11.57%.
Earnings released on 11 Feb 2021
EPS came in at -$0.26 surpassing the estimated -$0.48 by +45.83%, while revenue for the quarter reached $5.08M , missing expectations by -28.72%.
Earnings released on 10 Nov 2020
EPS came in at -$0.48 falling short of the estimated -$0.25 by -92.00%, while revenue for the quarter reached $5.06M , missing expectations by -95.22%.
RCEL Stock Performance
Access detailed RCEL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.